Yan Leyfman
Apr 14, 2025, 09:32
Yan Leyfman: Pluri Secures U.S. Patent for Immune Cell Expansion Technology
Yan Leyfman, Co-founder and executive director of MedNews Week, posted on LinkedIn:
“Pluri (Nasdaq: PLUR) announces a newly granted U.S. patent for its proprietary immune cell expansion technology, including MAIT cells — a unique subset of T cells with strong potential in solid tumor immunotherapy.
With over 250 patents now pending, allowed, or granted, this milestone strengthens Pluri’s leadership in scalable, placental-derived immune cell platforms.
Why it matters:
- MAIT cells have been difficult to expand outside the body — Pluri’s technology changes that.
- Proprietary 3D bioreactors mimic the natural immune environment.
- Enables “off-the-shelf” cell therapies.
- Low alloreactivity reduces the risk of GVHD and may enhance durability.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 12:02
Apr 15, 2025, 11:54
Apr 15, 2025, 11:52
Apr 15, 2025, 11:46
Apr 15, 2025, 11:30
Apr 15, 2025, 11:00
Apr 15, 2025, 10:23